Back

dr. M.A.E. (Minke) Rab MSc

dr. M.A.E. (Minke) Rab MSc

Assistant Professor
dr. M.A.E. (Minke) Rab MSc
  • Central Diagnostic Laboratory

Research Programs

Circulatory Health

Biography

Biography

Dr. Minke Rab is a Clinical Scientist, who graduated from medical school in 2010 after completing the Selective University Medical Masters (SUMMA) program at the UMCU, The Netherlands. In 2015 she started her PhD project on hereditary hemolytic anemias (UMCU, 2015-2019). After her internal medicine residency, she completed a two-year fellowship in Hematology (UMCU) while combining her clinical work with laboratory research. Thereafter, she has been appointed as hematologist at the Erasmus University Medical Center Rotterdam, where she is involved in the expertise center for hemoglobinopathies. Next to her clinical work, she works as assistant professor at the Central Diagnostic Laboratory-Research, UMCU on biomarker development in hereditary hemolytic anemias. A key achievement is the development of oxygenscan-related biomarkers reflecting RBC sickling on which she co-authored nine papers. She led the development of the oxygenscan from an early prototype stage into a technique that is now incorporated in various clinical trials in the US, Europe, and Africa.

Her research focusses on biomarker development in sickle cell disease and its applicability to assess novel therapies both in vitro and in vivo. For these kind of projects funding was obtained from Eurostars, RVO, Agios pharmaceuticals, Axcella Health and RR Mechatronics. It is the ambition of dr. Rab to further elucidate the crucial pathophysiological features of sickle cell disease, in order to find the best treatment, that is globally available, for this understudied disorder. Being a clinician-scientist, she is in an excellent position to bridge the gap between bench and bedside.

Research Output (20)

A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia

van Dijk Myrthe J., van Oirschot Brigitte A., Harrison Alexander N., Recktenwald Steffen M., Qiao Min, Stommen Amaury, Cloos Anne Sophie, Vanderroost Juliette, Terrasi Romano, Dey Kuntal, Bos Jennifer, Rab Minke A.E., Bogdanova Anna, Minetti Giampaolo, Muccioli Giulio G., Tyteca Donatienne, Egée Stéphane, Kaestner Lars, Molday Robert S., van Beers Eduard J., van Wijk Richard Dec 2023, In: American Journal of Hematology. 98 , p. 1877-1887 11 p.

Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease

Rab Minke A E, Kanne Celeste K, Boisson Camille, Bos Jennifer, van Oirschot Brigitte A, Houwing Maite, Renoux Céline, Bartels Marije, Rijneveld Anita W, Nur Erfan, Cnossen Marjon H, Joly Philippe, Nader Elie, Fort Romain, Connes Philippe, van Wijk Richard, Sheehan Vivien A, van Beers Eduard J 17 Nov 2023, In: Blood Advances. 8 , p. 276-286 11 p.

One-year safety and efficacy of mitapivat in sickle cell disease:follow-up results of a phase 2, open-label study

van Dijk Myrthe J, Rab Minke A E, van Oirschot Brigitte A, Bos Jennifer, Derichs Cleo, Rijneveld Anita W, Cnossen Marjon H, Nur Erfan, Biemond Bart J, Bartels Marije, Jans Judith J M, van Solinge W W, Schutgens Roger E G, van Wijk Richard, van Beers Eduard J 7 Nov 2023, In: Blood Advances. 7 , p. 7539-7550 12 p.

Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias:Shedding new light on an old enzyme

van Dijk Myrthe J, de Wilde Jonathan R A, Bartels Marije, Kuo Kevin H M, Glenthøj Andreas, Rab Minke A E, van Beers Eduard J, van Wijk Richard 12 Jun 2023, In: Blood Reviews. 61

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease:a phase 2, open-label study

van Dijk Myrthe J, Rab Minke A E, van Oirschot Brigitte A, Bos Jennifer, Derichs Cleo, Rijneveld Anita W, Cnossen Marjon H, Nur Erfan, Biemond Bart J, Bartels Marije, Jans Judith J M, van Solinge Wouter W, Schutgens Roger E G, van Wijk Richard, van Beers Eduard J 5 Apr 2022, In: American Journal of Hematology. 97 , p. E226-E229

Comment on:Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia

Sheehan Vivien A., van Beers Eduard J., Connes Philippe, van Wijk Richard, Rab Minke A.E. 2022, In: British Journal of Haematology. 197 , p. e61-e62

Effects of Genotypes and Treatment on Oxygenscan Parameters in Sickle Cell Disease

Boisson Camille, Rab Minke A E, Nader Elie, Renoux Céline, Kanne Celeste, Bos Jennifer, van Oirschot Brigitte A, Joly Philippe, Fort Romain, Gauthier Alexandra, Stauffer Emeric, Poutrel Solene, Kebaili Kamila, Cannas Giovanna, Garnier Nathalie, Renard Cécile, Hequet Olivier, Hot Arnaud, Bertrand Yves, van Wijk Richard, Sheehan Vivien A, van Beers Eduard J, Connes Philippe 5 Apr 2021, In: Cells. 10 , p. 1-11

Ektacytometry Analysis of Post-splenectomy Red Blood Cell Properties Identifies Cell Membrane Stability Test as a Novel Biomarker of Membrane Health in Hereditary Spherocytosis

Berrevoets M C, Bos J, Huisjes R, Merkx T H, van Oirschot B A, van Solinge W W, Verweij J W, Lindeboom M Y A, van Beers E J, Bartels M, van Wijk R, Rab M A E 25 Mar 2021, In: Frontiers in Physiology. 12 , p. 1-10

Decreased activity and stability of pyruvate kinase in sickle cell disease:a novel target for mitapivat therapy

Rab Minke A E, Bos Jennifer, van Oirschot Brigitte, Straaten Stephanie van, Kosinski Penelope A, Chubukov Victor, Kim Hyeryun, Mangus Heidi, Schutgens Roger E G, Pasterkamp Gerard, Dang Lenny, Kung Charles, van Beers Eduard J, van Wijk Richard 10 Mar 2021, In: Blood. 137 , p. 2997-3001 5 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Contact

Afspraken

Praktisch

hetwkz.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not